Federico Pea

12.2k total citations · 3 hit papers
278 papers, 7.5k citations indexed

About

Federico Pea is a scholar working on Pharmacology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Federico Pea has authored 278 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Pharmacology, 113 papers in Epidemiology and 96 papers in Infectious Diseases. Recurrent topics in Federico Pea's work include Antibiotics Pharmacokinetics and Efficacy (175 papers), Antibiotic Resistance in Bacteria (90 papers) and Pneumonia and Respiratory Infections (59 papers). Federico Pea is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (175 papers), Antibiotic Resistance in Bacteria (90 papers) and Pneumonia and Respiratory Infections (59 papers). Federico Pea collaborates with scholars based in Italy, United States and Spain. Federico Pea's co-authors include Pierluigi Viale, Mario Furlanut, Pier Giorgio Cojutti, Milo Gatti, Jeffrey Lipman, Jason A. Roberts, Stijn Blot, Federica Pavan, Massimo Baraldo and Matteo Bassetti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biomaterials and Advanced Drug Delivery Reviews.

In The Last Decade

Federico Pea

263 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

2020 640 citations Federico Pea, Jason A. Roberts et al. profile →
The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents

2014 315 citations Federico Pea et al. profile →
Challenges in the management of chronic wound infections

2021 181 citations Federico Pea, Stefania Stefani et al. profile →

Peers

Countries citing papers authored by Federico Pea

Since Specialization

Citations

This map shows the geographic impact of Federico Pea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Pea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Pea more than expected).

Fields of papers citing papers by Federico Pea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Pea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Pea. The network helps show where Federico Pea may publish in the future.

Co-authorship network of co-authors of Federico Pea

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Pea. A scholar is included among the top collaborators of Federico Pea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Pea. Federico Pea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis 2025 ·Therapeutic Drug Monitoring ·Milo Gatti, Pier Giorgio Cojutti, Matteo Rinaldi, Simone Ambretti, Maddalena Giannella, (unknown), Federico Pea	2
2	Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? 2025 ·Antimicrobial Agents and Chemotherapy ·Manjunath P. Pai, Pier Giorgio Cojutti, Milo Gatti, (unknown), Tommaso Tonetti, Antonio Daniele Pinna, Pierluigi Viale, Federico Pea	0
3	Rapid Emergence of Cefiderocol Resistance Associated with Mutation of EnvZ Gene in a VIM-Producing ST307 Klebsiella pneumoniae Strain 2025 ·Antibiotics ·Simone Ambretti, (unknown), (unknown), Milo Gatti, Pierluigi Viale, Federico Pea, Claudio Foschi	0
4	Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 2025 ·JAC-Antimicrobial Resistance ·(unknown), Pier Giorgio Cojutti, Milo Gatti, Federico Pea, Stefano Di Bella, Jacopo Monticelli	0
5	Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections? 2025 ·Antibiotics ·Pier Giorgio Cojutti, Sara Tedeschi, Eleonora Zamparini, Giacomo Fornaro, (unknown), Massimiliano De Paolis, Pierluigi Viale, Federico Pea	2
6	Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 2024 ·Antibiotics ·Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, Antonio Daniele Pinna, Pierluigi Viale, Federico Pea	2
7	Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 2024 ·Microorganisms ·Milo Gatti, Cecilia Bonazzetti, Renato Pascale, Maddalena Giannella, Pierluigi Viale, Federico Pea	2
8	Survey on the approach to antibiotic prophylaxis in liver and kidney transplant recipients colonized with “difficult to treat” Gram‐negative bacteria 2024 ·Transplant Infectious Disease ·Cecilia Bonazzetti, Matteo Rinaldi, Federica Cosentino, Milo Gatti, Maristela Pinheiro Freire, Alessandra Mularoni, Wanessa Trindade Clemente, Lı́gia Camera Pierrotti, José María Aguado, Paolo Grossi, Federico Pea, Pierluigi Viale, Maddalena Giannella, (unknown)	2
9	Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients 2024 ·Journal of Antimicrobial Chemotherapy ·Milo Gatti, Matteo Rinaldi, Cristiana Laici, Simone Ambretti, Antonio Daniele Pinna, Pierluigi Viale, Federico Pea	0
10	Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections 2024 ·Clinical Pharmacokinetics ·Pier Giorgio Cojutti, Sara Tedeschi, Eleonora Zamparini, Pierluigi Viale, Federico Pea	3
11	A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 2023 ·International Journal of Antimicrobial Agents ·Milo Gatti, Vincent H. Tam, Paolo Gaibani, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea	9
12	Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections 2023 ·International Journal of Antimicrobial Agents ·Pier Giorgio Cojutti, Milo Gatti, Nieko Punt, (unknown), Eleonora Zamparini, Sara Tedeschi, Pierluigi Viale, Federico Pea	9
13	Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients 2023 ·Pharmaceutics ·(unknown), Pier Giorgio Cojutti, Matteo Rinaldi, Cristiana Laici, Antonio Daniele Pinna, Pierluigi Viale, Federico Pea	7
14	Which Are the Best Regimens of Broad-Spectrum Beta-Lactam Antibiotics in Burn Patients? A Systematic Review of Evidence from Pharmacology Studies 2023 ·Antibiotics ·Gianpiero Tebano, (unknown), Luigi Raumer, Monica Cricca, Davide Melandri, Federico Pea, Francesco Cristini	0
15	Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections 2023 ·Antibiotics ·(unknown), Milo Gatti, Andrea Bedini, (unknown), Gabriella Orlando, Cinzia Puzzolante, Erica Franceschini, Marianna Menozzi, Antonella Santoro, Nicole Barp, Sara Volpi, (unknown), Federico Pea, Cristina Mussini, Marianna Meschiari	15
16	Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients 2023 ·Antimicrobial Agents and Chemotherapy ·Pier Giorgio Cojutti, Aaron J. Heffernan, Thomas Tängdén, Paola Della Siega, Carlo Tascini, Jason A. Roberts, Federico Pea	5
17	The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison 2022 ·Journal of Thrombosis and Thrombolysis ·Samantha Pasca, (unknown), Federico Pea, (unknown)	2
18	Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections 2021 ·JAC-Antimicrobial Resistance ·Marianna Meschiari, Sara Volpi, Matteo Faltoni, Giovanni Dolci, Gabriella Orlando, Erica Franceschini, Marianna Menozzi, Mario Sarti, (unknown), (unknown), (unknown), Paola Lanza, Silvia Lorenzotti, (unknown), Liana Signorini, (unknown), Milo Gatti, Federico Pea, Francesco Castelli, Cristina Mussini	43
19	Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient 2021 ·International Journal of Infectious Diseases ·Paolo Gaibani, Milo Gatti, Matteo Rinaldi, (unknown), Tiziana Lazzarotto, Maddalena Giannella, Donatella Lombardo, (unknown), Pierluigi Viale, Federico Pea, Simone Ambretti	16
20	Basic criteria for the appropriate and Accurate Use of Antibiotics: guidelines of the Italian Society of Chemoterapy. 2009 ·Journal of Chemotherapy ·Elisa Bertazzoni Minelli, F. Scaglione, A. De Sarro, Susanna Esposito, Delfino Legnani, Teresita Mazzei, Enrico Mini, Desiderio Passàli, Federico Pea, Stefania Stefani, I Viano, Andrea Novelli	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact